European Research Infrastructure for Translational Medicine
Budget
€10 — €0
EP Access
0
accredited persons
Staff
3
1.25 FTE
EU Grants
€1,954,809
Mission & Goals
EATRIS is a non-profit organisation (European Research Infrastructure Consortium) that provides access to a vast array of expertise and facilities from over 150 top-tier academic centres across Europe. EATRIS focuses on improving and optimising preclinical and early clinical development of drugs, vaccines and diagnostics, and overcome barriers to health innovation. In addition, EATRIS works with public funding agencies, charities and policy makers with tailored actions to help improve the translational research ecosystem. EATRIS policy efforts include raising the awareness on the impact of Translational Research, supporting the European research ecosystems to facilitate responsible research policies and engage society in the research and innovation decision-making processes; facilitating the digital transformation in Europe to unlock the power of data to improve health and, making meaningful patient engagement in translational research the new normal.
EU Legislative Interests
- AI Act, - EU general pharmaceuticals legislation, - EU Data Protection Regulation, - EU Health Data Space, - Implementation of the new In vitro diagnostics regulation and medical devices regulation, - Horizon Europe, EIC, EU4Health - ERIC regulation - Critical Medicine Act - EU Life Science Strategy - European Strategy for AI in science - Biotech Act
Communication Activities
Examples of communications and activities taking place at EATRIS includes the organisation of a policy workshops online and in person such as with social sciences and humanities stakeholders, the European Alliance for Social Sciences and Humanities (EASSH) and global publisher, Taylor and Francis highlighting the need for better structuring and funding of research translation across fields beyond life sciences; or the participation to additional policy workshops (invitation only expert meetings) to discuss the next research and innovation framework programme, the new pharmaceutical legislation, the next partnership on Personalized Medicine or the European Health Data Space. In addition, EATRIS contributes to the field and policy positioning with position papers, policy statements together with answering to public consultations: EATRIS policy statements can be found in a dedicated webpage: https://eatris.eu/advocacy-efforts/ In 2025 EATRIS so far answered to 9 consultations: - June 2025: EATRIS provides feedback on the EC consultation on the Biotech Act. - June 2025: EATRIS provides feedback on the EC consultation on the European Strategy for AI in science. - May 2025: EATRIS provides feedback on the EC consultation on the European strategy on research and technology infrastructures. - April 2025: EATRIS provides a response to the Public Consultation on the EU Life Sciences Strategy to rapidly developing, translating and commercialising innovative ideas and solutions in the EU. - March 2025: EATRIS has provided feedback on the “EU Start-up and Scale-up Strategy”, which outlines policy, financial, and legislative measures to enhance and streamline framework conditions for start-ups and scale-ups. - March 2025: Together with 38 other European health organisations, EATRIS co-signs the European Health Data Space (EHDS) Multi-Stakeholder Statement, urging policymakers to ensure meaningful stakeholder engagement and capacity building during EHDS implementation. The statement advocates for an inclusive, actionable process in shaping this new health data ecosystem. - February 2025: EATRIS provides a response to the Public Consultation on the “Critical Medicines Act” that addresses supply chain vulnerabilities of critical medicines and reduces Europe’s dependencies to strengthen the supply of critical medicines. More details here.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
EATRIS established partnerships with other research infrastructures and e-infrastructure providers to ensure that its researchers have access to the resources they need. EATRIS is an active member of EU-AMRI – a collaboration across EATRIS, BBMRI, and ECRIN. EATRIS is an observer of the EOSC Association, an active contributor to the EOSC development and is working to make its resources and data available through the EOSC portal. EATRIS is a member of the Personalised Medicine Coalition (PMC) and the Federation of European Academies of Medicine (FEAM). EATRIS is a partner of the EU Health Coalition.
Organisation Members
As an ERIC (European Research Infrastructure Consortium), the EATRIS internal governance is organised through its statutes, rules of procedure and standing order. The relationship between EATRIS-ERIC and its member institutions is organised through a link third party agreement, the EATRIS framework agreement signed by each institution individually (150+ institutions) EATRIS Member States - Ministry of Education and Science - Bulgaria - Ministry of Science and Education - Croatia - Ministry of Education, Youth and Sports - Czech Republic - Ministry of Education and Culture - Republic of Finland - Commissariat a l'Energie Atomique et aux Ennergies Alternatives - French Republic - Istituto Superiore di Sanita - Italian Republic - Ministry of Education and Science - Republic of Lativa - Le Gouvernement du grand-Duché de Luxembourg - the Grand Duchy of Luxembourg - ZonMW - Kingdom of the Netherlands - Research Council of Norway - Kingdom of Norway - INFARMED-National Authority of Medicines and Health Products - Republic of Portugal - Ministry of Education, Science and Sport - Republic of Slovenia - Instituto de Salud ‘Carlos III’ (ISCIII) - Kingdom of Spain - Vetenskapsrådet - Kingdom of Sweden - Ministry of Education, Research, Development and Youth - Slovak Republic
Commissioner Meetings
No recorded meetings with EU commissioners.